The absence of any of these disciplines can lead to blind spots that can introduce risk, but they are not all created equal.
All commercial, clinical, R&D and manufacturing activities surrounding the product will end.
Moving too quickly in the product development process can lead to mistakes.
An upcoming webinar will discuss the new methods and protocols that have emerged as a result of conducting trials and HF studies during the pandemic.
And medtech companies need to keep interoperability and security top of mind.
Part three of this series discusses the key defenses available to each element of a lawsuit against providers and labs.
To avoid delays in timelines, companies should develop IFU cleaning instructions with the worst-case clinical use and contamination method in mind.
Despite the high stakes of data vulnerabilities to the entire healthcare system, governments in Asia lag behind in mandating cybersecurity measures, leaving manufacturers to install and maintain systems to protect against cyber criminals.
Healthcare alliance group Premier discusses six issues that are at the forefront in the context of the 2020 election.
The pandemic is helping realize the potential of ISO IDMP data standards in relation to adverse event reporting, electronic prescribing and medicines control in the supply chain.